Kexing Biopharm Expands in Europe, Showcases Drugs at CPHI Milan

Kexing Biopharm participated in CPHI Milan 2026, held from October 6-8, 2026, to present its global pipeline of innovative drugs, co-developed biosimilars, and products marketed internationally. The company engaged with global pharmaceutical buyers, biotech firms, and industry partners during the event.

The company has built a substantial international marketing platform, entering into cooperation agreements for over 30 products for foreign markets. Its distribution network spans approximately 70 countries and regions, with nearly 200 overseas marketing authorization applications submitted. Europe is a key market for its core product, albumin-bound paclitaxel, which is already marketed in the EU and the UK.

With a strategic focus on "innovation + internationalization," Kexing Biopharm is developing over ten high-quality biosimilars for global markets, targeting areas such as cancer cachexia, ophthalmic diseases, systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD). To bolster its local presence in Europe, the company has established a subsidiary in Germany and plans to set up more subsidiaries in several other European countries.

Leveraging three decades of experience in industrial-scale biopharmaceutical production, Kexing Biopharm has established robust manufacturing and quality management systems. Its albumin-bound paclitaxel production line holds EU GMP certification. The company intends to continue driving innovation and marketing high-quality medicines globally through its partnerships.